Danaher Corporation
DHR
$202.63
+0.09%
Danaher Corporation is a global science and technology innovator, designing and manufacturing medical diagnostics, life sciences tools, and biotechnology instruments and consumables. Following the late 2023 divestiture of its environmental solutions business (Veralto), Danaher has sharpened its focus on high-growth healthcare and life sciences end markets, positioning itself as a leading pure-play provider of advanced diagnostic and research solutions. The current investor narrative centers on the company's strategic pivot toward bioprocessing and genomics, with recent headlines highlighting its acquisition of Masimo and a temporary shipment delay in its biotech segment that sparked a sharp but potentially overdone selloff. Debates revolve around whether the company can sustain its innovation-driven growth and margin expansion amid cyclical biotech funding headwinds and integration risks from recent M&A.…
DHR
Danaher Corporation
$202.63
Related headlines
Investment Opinion: Should I buy DHR Today?
Rating: Buy. Danaher is a high-quality healthcare company with a strong competitive position, and the current valuation is reasonable on forward earnings. The consensus rating is Strong Buy with an average target of $227.96, implying 12.6% upside. The thesis is that the company's recurring revenue and margin expansion will drive EPS growth, justifying the forward PE of 21.8x.
Sign up to view all
DHR 12-Month Price Forecast
The AI assessment leans bullish, as the forward valuation is reasonable and the company has a strong recurring revenue base. However, confidence is medium due to operational risks and the high trailing PE. The key is whether earnings growth materializes as expected. If Q2 2026 earnings show strong EPS growth and the biotech delays are resolved, the stock could outperform. Conversely, if growth disappoints, the stock could de-rate. I would upgrade to high confidence if revenue growth exceeds 5% and margins expand, and downgrade to neutral if shipment delays persist or the Masimo integration shows signs of trouble.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $227.96 and implied upside of +12.5% versus the current price.
Average Target
$227.96
0 analysts
Implied Upside
+12.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
Danaher is covered by 23 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.5 (where 1 is Strong Buy and 5 is Sell). The average price target is $227.96, implying an upside of approximately 12.6% from the current price of $202.45. The distribution of ratings is heavily skewed toward bullish, with recent actions from firms like Evercore ISI (Outperform), HSBC (Buy), and Morgan Stanley (Overweight) reinforcing the positive sentiment. However, Citigroup downgraded from Buy to Neutral in May 2026, and Piper Sandler maintains a Neutral stance, indicating some caution among a minority of analysts.
Bulls vs Bears: DHR Investment Factors
Danaher presents a classic quality-growth debate. On the bull side, the company boasts a strong recurring revenue base, impressive margins, and a forward PE of 21.8x that appears reasonable if earnings grow as expected. Analyst consensus is strongly bullish with a 12.6% upside to the average target. On the bear side, the trailing PE of 45.2x and negative PEG suggest the stock is not cheap, and recent operational hiccups (biotech delays) plus integration risks from Masimo add uncertainty. The most important tension is whether the market's expectation of a significant earnings recovery (implied by the forward PE) will materialize. If it does, the stock is undervalued; if not, the high trailing multiple could compress. Currently, the evidence slightly favors the bull case given the strong analyst support and the company's proven ability to execute, but the margin of safety is thin.
Bullish
- Strong Buy consensus with 12.6% upside: 23 analysts rate DHR a Strong Buy (mean 1.5), with an average price target of $227.96, implying 12.6% upside from the current $202.45. Recent upgrades from Evercore ISI, HSBC, and Morgan Stanley reinforce positive sentiment.
- Forward PE of 21.8x is attractive: The trailing PE of 45.2x drops to 21.8x on forward earnings, signaling the market expects significant EPS growth. This forward multiple is reasonable for a high-quality healthcare compounder and below its historical average.
- Recurring revenue provides stability: Recurring revenue of $5.03B in Q1 2026 accounts for 84.5% of total revenue, providing a resilient base. This recurring stream supports consistent cash flows and reduces volatility.
- Strong profitability metrics: Gross margin is 60.9% and operating margin is 20.9%, reflecting a high-quality business model. Net margin of 14.7% and ROE of 6.9% (though modest) indicate solid capital efficiency.
Bearish
- Trailing PE of 45.2x is rich: The trailing PE of 45.2x is well above the market average and DHR's own historical norms. If earnings growth disappoints, the stock could face multiple compression.
- Negative relative strength over 1 year: DHR is down 3.7% over the past year while the S&P 500 is up 20.4%, resulting in a relative strength of -24.1%. This underperformance may persist if the company fails to beat growth expectations.
- Biotech shipment delays create uncertainty: Temporary shipment delays in the biotech segment caused a sharp selloff, highlighting operational risks. If delays persist, they could impact near-term revenue and analyst estimates.
- Masimo acquisition integration risk: The acquisition of Masimo adds integration complexity and was viewed as 'conservative' rather than transformative. If synergies fail to materialize, it could drag on margins and returns.
DHR Technical Analysis
Danaher's stock has been in a broad recovery phase over the past year, with the current price of $202.45 representing a 3.7% decline from a year ago, but a notable 25.0% gain over the last three months. The stock is trading at approximately 83% of its 52-week range (between $160.93 low and $242.80 high), indicating it has rebounded significantly from its lows but remains below its highs. This positioning suggests a mix of improving momentum and lingering caution, as the stock has not yet reclaimed its previous peak, which could signal either a continuation of the recovery or resistance ahead.
Beta
0.80
0.80x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
-3.9%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +4.0% |
| 3m | +21.3% | +5.3% |
| 6m | -2.8% | +12.6% |
| 1y | -3.9% | +20.1% |
| ytd | -12.1% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows a modest but steady growth pattern, with the most recent quarter (Q1 2026) reporting revenue of $5.951 billion, up 3.7% year-over-year. This follows a sequential trend of $6.838 billion in Q4 2025, $6.053 billion in Q3 2025, and $5.936 billion in Q2 2025, indicating a slight deceleration from the Q4 peak but overall stability. The recurring revenue segment, which accounts for $5.031 billion of total revenue, underscores the company's resilient business model, while nonrecurring revenue of $0.92 billion adds a variable component. The growth is primarily driven by demand for life sciences tools and diagnostics, though biotech shipment delays have created temporary headwinds.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given Danaher's positive net income, the price-to-earnings (PE) ratio is the most appropriate primary valuation metric. The trailing PE stands at 45.15x, while the forward PE is 21.77x, implying the market expects significant earnings growth over the next year. This wide gap between trailing and forward multiples suggests that the market is pricing in a substantial recovery in profitability, likely driven by margin expansion and cost synergies from recent acquisitions. The forward PE of 21.77x is more in line with historical norms for a high-quality healthcare company, indicating that the current valuation may be reasonable if earnings growth materializes as expected.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks: Danaher's debt-to-equity ratio is 0.35, which is manageable, but the company's net income has been volatile, with Q2 2025 EPS of $0.77 versus $1.45 in Q1 2026. The trailing PE of 45.2x implies high expectations; if earnings growth stalls, the stock could de-rate. Free cash flow is strong at $5.29B TTM, but the payout ratio of 24.3% and dividend yield of 0.54% offer limited income support. Revenue concentration in life sciences and diagnostics exposes the company to biotech funding cycles, as seen in the recent shipment delays.